Fecha de publicación: -- Fuente: Labiotech Lugar: Top Pharma Strategy While Teva is initially known for its generics business, the company is shifting its strategy to build a more innovative pipeline.
The post Teva’s pipeline in 2027: Can it sustain its transformation?  appeared first on Labiotech.eu.
© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.